Safety news
By: Who Press
.
Publisher: Switzerland World Health Organization 2018Edition: Vol. 32(2).Description: 199-207.Subject(s): DRUG STORE MANAGEMENTOnline resources: Click here
In:
Who drug informationSummary: Ireland, Estonia – The marketing
authorization holder, in agreement with
EMA and national regulatory authorities,
has informed health professionals
about an increased rate of relapses
of haematological malignancies and
mortality in haematopoietic stem cell
transplantation (HSCT) patients treated
experimentally with azithromycin. A clinical
trial investigating the use of azithromycin to
prevent bronchiolitis obliterans syndrome
following HSCT was terminated early
after an increased risk of relapses was seen
compared with placebo. The researchers
conclude that long term azithromycin
exposure following HSCT may include risks
which exceed the anticipated benefits
| Item type | Current location | Call number | Status | Date due | Barcode | Item holds |
|---|---|---|---|---|---|---|
Articles Abstract Database
|
School of Pharmacy Archieval Section | Not for loan | 2018268 |
Ireland, Estonia – The marketing
authorization holder, in agreement with
EMA and national regulatory authorities,
has informed health professionals
about an increased rate of relapses
of haematological malignancies and
mortality in haematopoietic stem cell
transplantation (HSCT) patients treated
experimentally with azithromycin. A clinical
trial investigating the use of azithromycin to
prevent bronchiolitis obliterans syndrome
following HSCT was terminated early
after an increased risk of relapses was seen
compared with placebo. The researchers
conclude that long term azithromycin
exposure following HSCT may include risks
which exceed the anticipated benefits
There are no comments for this item.